EMEA-000170-PIP03-13-M03

Key facts

Invented name
Revolade
Active substance
Eltrombopag
Therapeutic area
Haematology-Hemostaseology
Decision number
P/0280/2017
PIP number
EMEA-000170-PIP03-13-M03
Pharmaceutical form(s)
  • Film-coated tablet
  • Powder for oral suspension
Condition(s) / indication(s)
Treatment of aplastic anaemia
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited

Tel. +41 6132 41111
E-mail: paediatric.enquiries@novartis.com

Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating